Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02 Results of Operations and Financial Condition. The disclosure set forth in Item 7.01 of this Current Report is incorporated herein by reference.
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”).
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
The
disclosure set forth in Item 7.01 of this Current Report is incorporated herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
January 13, 2026, the Company issued a press release announcing that it had reported exceptional year-over-year revenue growth, stronger
gross margins, and improved operating performance in its recently filed Form 10-Q for the Quarter ended April 30, 2026.
A
copy of the press release is included with this Current Report as Exhibit 99.1.
Regulation
FD Disclosure
The
information set forth in Items 2.02 and 7.01 of this Current Report and in the press release included
as Exhibit 99.1 to this Current Report is deemed to be “furnished” and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject
to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current
Report and in the press release included as Exhibit 99.1 to this Current Report shall not be deemed incorporated by
reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “ Securities Act ”),
regardless of any general incorporation language in such filing.
Forward-Looking
Statements
This
Current Report and the press release included as Exhibit 99.1 to this Current Report contains statements which should
be considered forward-looking statements within the meaning of the Securities Act, the Exchange Act and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes
that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties,
and these expectations may prove to be incorrect. Actual results could vary dramatically. You should not place undue reliance on forward-looking
statements. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Filed exhibits (1)
EX-99.1 (by filename) zeoscientifix_ex99-1.htm
EX-99.1
2
zeoscientifix_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
ZEO ScientifiX Reports Strong Revenue Growth Of For Three Months and Six Months Ended April 30, 2026
Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum accelerates across its regenerative biologics portfolio.
DAVIE,
FLORIDA - July 8, 2026 - ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”),
a biologics research and products company advancing regenerative medicine, physician education, and next-generation biologic technologies,
today announced that it had reported exceptional year-over-year revenue growth, stronger gross margins, and improved operating performance
in its recently filed Form 10-Q for the Quarter ended April 30, 2026 (the “Form 10-Q”).
In the Form 10-Q, the Company provided the following information:
“ Revenues. Our revenues for the three months ended April 30, 2026 were $2,581,000, as compared to revenues of $1,149,000 for the three months ended April 30, 2025. The increase in revenues for the three months ended April 30, 2026 of …
